PT  - JOURNAL ARTICLE
AU  - Milross, Luke
AU  - Hunter, Bethany
AU  - McDonald, David
AU  - Merces, George
AU  - Thompson, Amanda
AU  - Hilkens, Catharien M.U.
AU  - Wills, John
AU  - Rees, Paul
AU  - Jiwa, Kasim
AU  - Cooper, Nigel
AU  - Majo, Joaquim
AU  - Ashwin, Helen
AU  - Duncan, Christopher J.A.
AU  - Kaye, Paul M.
AU  - Bayraktar, Omer Ali
AU  - Filby, Andrew
AU  - Fisher, Andrew J.
TI  - Distinct lung cell signatures define the temporal evolution of diffuse alveolar damage in fatal COVID-19
AID  - 10.1101/2023.05.05.23289594
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.05.23289594
4099  - http://medrxiv.org/content/early/2023/05/07/2023.05.05.23289594.short
4100  - http://medrxiv.org/content/early/2023/05/07/2023.05.05.23289594.full
AB  - Background Lung damage in severe COVID-19 is highly heterogeneous however studies with dedicated spatial distinction of discrete temporal phases of diffuse alveolar damage (DAD) and alternate lung injury patterns are lacking. Existing studies have also not accounted for progressive airspace obliteration in cellularity estimates. We used an imaging mass cytometry (IMC) analysis with a novel airspace correction step to more accurately identify the cellular immune response that underpins the heterogeneity of severe COVID-19 lung disease.Methods Lung tissue was obtained at post-mortem from severe COVID-19 deaths. Pathologist-selected regions of interest (ROIs) were chosen by light microscopy representing the patho-evolutionary spectrum of DAD and alternate disease phenotypes were selected for comparison. Architecturally normal SARS-CoV-2-positive lung tissue and tissue from SARS-CoV-2-negative donors served as controls. ROIs were stained for 40 cellular protein markers and ablated using IMC before segmented cells were classified. Cell populations corrected by ROI airspace and their spatial relationships were compared across lung injury patterns.Results Forty patients (32M:8F, age:22-98), 345 ROIs and >900k single cells were analysed. DAD progression was marked by airspace obliteration and significant increases in mononuclear phagocytes (MnPs), T and B lymphocytes and significant decreases in alveolar epithelial and endothelial cells. Neutrophil populations proved stable overall although several interferon-responding subsets demonstrated expansion. Spatial analysis revealed immune cell interactions occur prior to microscopically appreciable tissue injury.Conclusions The immunopathogenesis of severe DAD in COVID-19 lung disease is characterised by sustained increases in MnPs and lymphocytes with key interactions occurring even prior to lung injury is established.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was partly funded by UKRI/Medical Research Council through the UK Coronavirus Immunology Consortium (UK-CIC) as well as the Barbour Foundation. L Milross was supported by a General Sir John Monash Scholarship awarded by the General Sir John Monash Foundation and a Vice-Chancellors Global Scholarship from Newcastle University in support of a Master of Research in Immunobiology at Newcastle University. A Thomspon was supported by funding from the JGW Patterson Foundation. C. J. A. Duncan was supported by a Wellcome Clinical Research Career Development Fellowship (211153/Z/18/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of North East - Newcastle & North Tyneside 1 Research gave ethical approval for this work. Ethics committee of the Wales Research Ethics Committee 3 gave ethical approval for this work. Ethics committee of the East of Scotland Research Ethics Service gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors